Trial Profile
A retrospective chart review comparing 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients and those who had received TNFα inhibitors or no biologic therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- 03 Jan 2018 New trial record
- 18 Dec 2017 Results published in the Alimentary Pharmacology and Therapeutics